L3VLUP
ProSign in

XRAY · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

XRAYVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • XRAY
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterXRAYVRTX
Q3 202014 holders, $2.3bn31 holders, $21.9bn
Q4 202011 holders, $2.7bn30 holders, $18.4bn
Q1 202116 holders, $3.7bn31 holders, $15.4bn
Q2 202123 holders, $3.8bn30 holders, $12.7bn
Q3 202118 holders, $3.3bn35 holders, $10.1bn
Q4 202113 holders, $2.8bn28 holders, $12.4bn
Q1 202216 holders, $2.8bn23 holders, $16.1bn
Q2 202218 holders, $2.0bn25 holders, $18.1bn
Q3 202217 holders, $1.5bn22 holders, $18.4bn
Q4 202214 holders, $1.6bn28 holders, $18.4bn
Q1 202311 holders, $2.2bn26 holders, $21.4bn
Q2 202310 holders, $1.9bn27 holders, $24.7bn
Q3 202315 holders, $1.7bn33 holders, $24.3bn
Q4 202313 holders, $1.7bn32 holders, $28.6bn
Q1 202412 holders, $1.1bn31 holders, $29.8bn
Q2 20249 holders, $781m29 holders, $33.4bn
Q3 20248 holders, $941m27 holders, $33.5bn
Q4 20249 holders, $648m26 holders, $28.5bn
Q1 20259 holders, $586m21 holders, $35.4bn
Q2 20258 holders, $639m21 holders, $32.3bn
Q3 20256 holders, $369m22 holders, $25.9bn
Q4 20255 holders, $199m26 holders, $31.8bn
Q1 20267 holders, $273m25 holders, $31.8bn
Q2 20265 holders, $61m26 holders, $34.6bn
XRAY

Dentsply Sirona Inc

Holders
13
Reported value
$1.7bn
Buyers
9
Sellers
7

Breadth +2 among 93 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
VRTX

Vertex Pharmaceuticals Inc

Holders
32
Reported value
$28.6bn
Buyers
16
Sellers
16

Breadth 0 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2023

Among the 37 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only XRAY (5)

Arrowstreet Capital LP, ExodusPoint Capital Management LP, First Eagle Investment Management LLC, GAMCO Investors Inc, Quantbot Technologies LP

Only VRTX (24)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Brevan Howard Capital Management LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, D. E. Shaw & Co., Farallon Capital Management LLC, Fidelity (FMR LLC), Hudson Bay Capital Management LP, Invesco Ltd, Man Group PLC, Maverick Capital Ltd, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, PDT Partners LLC, Renaissance Technologies LLC, Tudor Investment Corp, Two Sigma Advisers LP, Two Sigma Investments LP, Voloridge Investment Management LLC, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →